收藏切换
Analysis of the therapeutic effect of fenalnidone combined with dapagliflozin in the treatment of diabetic nephropathy
收藏切换
Yinghui JIANG1a, 2, Wenying SHANG3, Xiaojuan ZHANG4, Shilei ZHANG1b, Weiwei LU1a, Zheng LI2
World Clinical Drug | 2026, 47(5) : 486 - 494
Less
收藏切换
World Clinical Drug | 2026, 47(5): 486-494
• Article •
Analysis of the therapeutic effect of fenalnidone combined with dapagliflozin in the treatment of diabetic nephropathy
Full
Yinghui JIANG1a, 2, Wenying SHANG3, Xiaojuan ZHANG4, Shilei ZHANG1b, Weiwei LU1a, Zheng LI2
Affiliations
  • 1a.Department of Nephrology, Shijiazhuang Medical College Hospital, Shijiazhuang 050093, Hebei Province, China
  • 1b.Department of Oncology, Shijiazhuang Medical College Hospital, Shijiazhuang 050093, Hebei Province, China
  • 2.Department of Nephrology, Hebei Hepatopathy Hospital of Traditional Chinese Medicine, Shijiazhuang 055550, Hebei Province, China
  • 3.Department of Laboratory, Shijiazhuang Zhongbao Outpatient Department, Shijiazhuang 050011, Hebei Province, China
  • 4.Department of Traditional Chinese Medicine, Hebei Maternity Hospital, Shijiazhuang 050090, Hebei Province, China
Published: 2026-05-10 doi: 10.13683/j.wph.2026.05.005
Outline
收藏切换
Objective

To explore the therapeutic effect of fenofibrate combined with dapagliflozin in the treatment of diabetic nephropathy(DN).

Methods

This study was a prospective randomized controlled trial. 500 patients with DN who admitted to the department of nephrology, Hebei hepatopathy hospital of traditional Chinese medicine from January 2021 to January 2024 were selected and randomly divided into the control group and the observation group, with 250 cases in each group. The control group was treated with dapagliflozin orally, while the observation group was treated with fenofibrate in addition to the treatment of the control group. Both groups were treated continuously for 12 months. The primary endpoint was the renal composite hard endpoint[defined as a declinein estimated glomerular filtration rate(eGFR)of ≥40% or progression to end-stage renal disease] at 12 months of treatment, and the secondary endpoints included differences in blood glucose indicators, renal function indicators, inflammatory factors, microcirculation indicators,oxidative stress indicators before treatment, at 6 and 12 months of treatment, as well as safety comparisons.

Results

After 12 months of follow-up, the incidence of the renal composite hard endpoint in the observation group was lower than that in the control group(P<0.05). At 6 and 12 months, the fasting blood glucose, glycosylated hemoglobin, serum creatinine,24-hour urinary microprotein excretion rate, β2 microglobulin, C-reactive protein, interleukin-6, endothelin-1, fibrinogen,whole blood low shear viscosity, malondialdehyde in the observation group were lower than those in the control group,while the superoxide dismutase and glutathione peroxidase were higher than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).

Conclusion

Fenofibrate combined with dapagliflozin can significantly reduce the risk of the renal composite hard endpoint in patients with DN, demonstrating a clear long-term renal protective effect. It may achieve this through multiple pathways such as synergistically regulating blood glucose, protecting renal function, inhibiting the systemic inflammation, improving microcirculation, and reducing oxidative stress damage. Moreover, it does not increase adverse reactions, with good safety.

diabetic nephropathy  /  fenofibrate  /  dapagliflozin  /  inflammation  /  microcirculation  /  oxidative stress
蒋莹辉, 尚文英, 张晓娟, 张石磊, 卢伟伟, 李铮. 非奈利酮联合达格列净治疗糖尿病肾病的效果分析. 世界临床药物, 2026 , 47 (5) : 486 -494 . DOI: 10.13683/j.wph.2026.05.005
Yinghui JIANG, Wenying SHANG, Xiaojuan ZHANG, Shilei ZHANG, Weiwei LU, Zheng LI. Analysis of the therapeutic effect of fenalnidone combined with dapagliflozin in the treatment of diabetic nephropathy[J]. World Clinical Drug, 2026 , 47 (5) : 486 -494 . DOI: 10.13683/j.wph.2026.05.005
Year 2026 volume 47 Issue 5
58
15
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2026.05.005
  • Receive Date:2025-09-28
  • Online Date:2026-11-05
  • Published:2026-05-10
Article Data
Affiliations
History
  • Received:2025-09-28
  • Revised:2026-01-26
Funding
Affiliations
    1a.Department of Nephrology, Shijiazhuang Medical College Hospital, Shijiazhuang 050093, Hebei Province, China
    1b.Department of Oncology, Shijiazhuang Medical College Hospital, Shijiazhuang 050093, Hebei Province, China
    2.Department of Nephrology, Hebei Hepatopathy Hospital of Traditional Chinese Medicine, Shijiazhuang 055550, Hebei Province, China
    3.Department of Laboratory, Shijiazhuang Zhongbao Outpatient Department, Shijiazhuang 050011, Hebei Province, China
    4.Department of Traditional Chinese Medicine, Hebei Maternity Hospital, Shijiazhuang 050090, Hebei Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2026.05.005
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT